MariMed Inc. (OTC:MRMD) Q3 2022 Earnings Call Transcript

MariMed Inc. (OTC:MRMD) Q3 2022 Earnings Call Transcript November 8, 2022

MariMed Inc. reports earnings inline with expectations. Reported EPS is $0.01 EPS, expectations were $0.01.

Operator: Good morning. My name is Pam, and I will be your conference operator today. At this time, I would like to welcome everyone to the MariMed Third Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. Thank you. I would now like to turn the conference call over to Mr. Steve West, Vice President of Investor Relations. Please go ahead.

Photo by David Gabrić on Unsplash

Steve West: Good morning, everyone, and welcome to MariMed’s third quarter 2022 conference call. Joining me on the call today are Bob Fireman, our Chief Executive Officer; Jon Levine, our President; Tim Shaw, our Chief Operating Officer; and Susan Villare, our Chief Financial Officer. This call is being recorded and will be archived on our Investor Relations website at ir.marimedinc.com. Today’s call contains forward-looking statements subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those forward-looking statements. These risks and uncertainties are discussed in our documents filed with the SEC, including our most recent Form 10-K and Form 10-Q. Any forward-looking statements reflect the management’s expectations as of today’s date, and we assume no obligation to update them other than as may be required by applicable securities laws.

In addition, we will present non-GAAP financial information on this call. Reconciliations to applicable GAAP financial measures are included in our earnings release, as well as in the supplemental slides, which are available on our Investor Relations website. For your future scheduling purposes, our fourth quarter 2022 earnings release is tentatively scheduled to be issued after the market closes on March 1, 2023, and our subsequent analyst call will be held the morning of November 2, 2023. I will now turn the call over to Bob.

Bob Fireman: Thank you, Steve, and good morning, everyone. I am pleased to report that MariMed had another solid quarter of financial and operational results. Our revenue continues to increase both year-over-year and quarter-over-quarter. Most importantly, we are reporting positive adjusted EBITDA for the 11th consecutive quarter. We continued to successfully execute on our strategic growth plan during the third quarter, advancing several significant milestones. These milestones include assets and resources to further increase our company’s revenue and earnings. We are pleased that we are outperforming our competitors in terms of sales growth in all our key markets, the headwinds of inflation from COVID, the war in Ukraine, the price compression have not taken MariMed off our course.

This is the result of the quality of our products and services as well as the culture and excellence of our team. We are hopeful that President Biden’s new cannabis policy statement and other initiatives at the federal level will improve capital market access the U.S. cannabis company to list on senior exchanges. This will allow more institutional investors to participate in our success. MariMed is poised to continue to grow up to $400 million in revenue in the next few years as one of the few MSOs with a clean balance sheet, operational excellence, strong financial discipline, and is profitable. We are well positioned as a transformational M&A participant. Rest assured, any transaction seriously considered must be accretive and improved MariMed shareholder value.

I suggest you all keep watching the MariMed’s story. Let me now turn it over to Jon. Thank you.

Jon Levine: Good morning, everyone. As Bob said, we had another solid quarter. First, we completed the expansion of our state-of-the-art kitchen in Maryland, which allows us to manufacture, sell, and distribute our award-winning products, including Betty’s Eddies and Bubby’s Baked. Second, we acquired dispensary license in Illinois, which will be in the eastern part of the state near the Indiana border. Once completed and approved to open, it will be our fifth thrive dispensary in Illinois. Third, we launched three new products. In Massachusetts, we launched Betty’s Eddies ice cream and Nature’s Heritage LIVE Flower, which are both selling very well. Also in Maryland, we launched a line of gummies under our in-house brand. We continue to innovate with new brands and products that address consumer needs.

Fourth, we partnered with a processing license holder in Missouri to develop and manage a state-of-the-art kitchen to produce and sell all of our award-winning edibles in the wholesale market. We hope Missouri voters will pass adult use ballot initiative at the polls today. And fifth, we entered into a manufacturing contract with 42 degrees. A leading distributor in Michigan, 42 degrees will sell our award-winning Betty’s Eddies fruit juice with the intention of expanding to include our other brands in the future, 42 Degrees has an extensive sales force and currently wholesales into 340 dispensaries for about 75% of Michigan dispensaries. Our momentum continues into the fourth quarter, as we recently announced the opening of our first dispensary in Maryland and officially achieved full vertical integration in that state.

We remain focused on maintaining our financial discipline, building great brands and executing our strategic growth plan. Our core retail business continues to strengthen and our wholesale business is gaining momentum despite flower pricing pressures. While the overall industry remains challenged, we are focused on operating great at retail and wholesale, and by delivering outstanding customer service, we will continue to outperform the industry. With that, I will turn the call over to Tim for operational update.

Tim Shaw: Thank you, Jon, and good morning, everyone. Let me begin our operations review with retail where we grew revenue by 2% sequentially compared to the second quarter. Our sequential growth was comprised of 10% transaction growth, which was offset in part by a decrease on the average ticket. The country is experiencing historic inflation in nearly every state with a cannabis program reported slowing or negative growth in the third quarter compared to the second quarter. To say where we are overjoyed that MariMed was able to buck this trend is an understatement. We worked extremely hard to fight the right balance of premium and value offerings, extended hours, new product launches, advertising and delivery services, and these initiatives are paying off.

We received more great news a few weeks ago when Maryland regulators approved the opening of our Annapolis dispensary. While we are still awaiting regulatory approval for our dispensary in Massachusetts, we are optimistic it will open in the coming months. Under wholesale, our sales increased 13% sequentially, primarily due to our performance in Maryland, which increased 53% compared to the second quarter. In Massachusetts, which also reported positive sequential growth. We have seen wholesale price compression in flower compared to last year, but it remains stable in Massachusetts and Maryland is showing signs of stability. The good news is we’re able to offset most of that price compression by introducing our in-house branded value products, which now account for about 20% of our total sales.

This includes Maryland where we launched our in-house vapes late in the second quarter shortly after we launched a line of 10 milligram gummies. In Maryland, our branded edibles such as Betty’s Eddies, and Bubby’s Baked are literally selling faster than we can produce them. As a result, we’re significantly increasing our staffing to run multiple production shifts per day, seven days a week, while this has been a difficult year for the wholesale in Maryland. We have the parts in place and ability to ramp up production and sales to quickly meet the unprecedented demand for our edibles. Before I finish, I’d like to share some exciting news. We recently received the necessary local and state approvals to begin hydrocarbon extracting in Massachusetts, which allows us to produce our own derivative extracts such as live resin butter and diamonds and sauce.

We will also begin producing Nature’s Heritage branded live resin and sauce carts, which will be available in select dispensaries by year end. And finally, on the products front, as Jon mentioned, we continue to innovate and develop products that address what today’s cannabis consumer wants. Data and customer feedback showed us that they want their edibles to deliver specific benefits. Just a couple weeks ago, we improved our top selling Betty’s Eddies lineup by adding some new products, improving others while keeping some of the fan favorites unchanged. Every chew is now custom formulated to help address basic needs such as a better sleep, pain relief, stress relief, increased libido, and others. Great brands will win in cannabis, and we are confident ours will be among the long-term champions.

That concludes my operations review. I will now transfer the call to Susan who will go over our financial results.

See also 12 Best Beaten Down Stocks To Buy and 11 Best Las Vegas Stocks To Invest In.

Susan Villare: Thank you, Tim, and good morning, everyone. I would like to start a brief recap of our third quarter financial results. Total revenue was $33.9 million, which increased nearly $1 million for about 3% sequentially. This is driven by both our dispensary and wholesale operations, partially offset by lower revenue from other sources such as rental income and management fees. I want to provide some more market data within the states we operate that Tim briefly touched upon. External reports show this being the third quarter sequentially that sales load both in Illinois and Massachusetts, while declining in Maryland. I am pleased to know MariMed’s dispensaries saw flat to positive traffic growth versus the previous quarter at every single dispensary for the second consecutive quarter.

MariMed’s outperformance against these unfavorable market trends is a testament for award-winning dispensary and brands. Moving to gross margins. Our non-GAAP gross margin was 48% compared to 46% last quarter. The gross margin improvement was primarily attributable to our increased sales of our branded products in the wholesale markets of Maryland and Massachusetts. We continue to believe our second quarter gross margins was a low watermark and we expect our margins to continue to improve and stabilize. Moving to non-GAAP operating expenses. We continue to be very disciplined with our discretionary spending. Our non-GAAP operating expenses increased $1.6 million sequentially to $8.7 million in the third quarter. This sequential increase was due to plan increases in both personnel and marketing programs to support our strategic growth initiative.

Our adjusted EBITDA was $8.7 million, which represents a 25% margin. This was down sequentially versus a second quarter adjusted EBITDA margin of 27% due to our plan increases in operating expenses. Now turning to the balance sheet. We ended the third quarter with $11.1 million of cash and equivalents, which increased versus our second quarter cash balance of $7.9 million due to our continued ability to generate positive cash flow from operations. Our networking capital increased to $13.6 million from $8.3 million at the end of the second quarter. Our ability to generate cash remains a core strength of MariMed as illustrated by our year-to-date positive cash flow from operations. We remain on track to be cash flow positive for the full year.

Now, with respect to our full year 2022 guidance, we are now assuming that our new adult-use dispensary in Beverly, Mass, which has been on the ready to open since early summer, will not open until 2023. We continue to face regulatory timing delays, but we remain optimistic that they will be resolved in the near term. Additionally, we are assuming that the pricing pressure will continue in the states where we operate, both on the wholesale and retail front. Accordingly, we expect full year revenue to be in the range of $132 million to $135 million, which represents a year-over-year growth rate of 9% to 11%. Our full year non-GAAP gross margin outlook is between 48% and 49%, which is slightly lower than our previous guidance of 50% due to the deleverage associated with the delayed revenue from our unopened dispensary.

Our adjusted non-GAAP EBITDA forecast is between $33 million and $35 million. Finally, our full year CapEx spend is estimated to be between $16 million and $17 million. That concludes my prepared remarks. And at this time, I would like to now turn the call back over to Jon for his concluding comments.

Jon Levine: Thank you, Susan. We are incredibly proud of delivering another strong quarter of operational and financial results, which remains some of the strongest in the industry. Before closing, I want to acknowledge the positive progress towards cannabis reform we are seeing at the federal level. Hopefully, the momentum of the President’s recent announcement will have a domino effect of safe banking finally passing. In the meantime, we will continue to focus our attention on executing our strategic growth plan. As we noted earlier, despite the significant headwinds facing consumers in the U.S., we continue to report improving sales trends in both our retail and wholesale businesses. Looking ahead, 2022 remain a foundational year, and we continue to be very bullish about next year.

In addition to Maryland dispensary we just opened in Annapolis, we expect several new assets to come online in 2023 to help drive accelerated growth. In retail, we anticipate opening dispensaries in Ohio, Massachusetts, and Illinois. In wholesales, we expect our new production kitchens in Illinois and Missouri to be completed. We also expect our new cultivation facility in Illinois and our expanded cultivation in Massachusetts to become operational in 2023. And we remain very active in discussions for additional accretive acquisitions. To summarize, we are financially solid and poised for continued long-term growth and success. We continue to improve our sales trends at both retail and wholesale in our key states. Our great foundation of revenue producing assets will allow us to continue growing organically and generate positive cash flow to further strengthen our balance sheet.

We’re extremely excited about MariMed’s prospects for 2023. I would like to thank all of our MariMed employees for their hard work and dedication, making us one of the best run and financially found cannabis companies. Operator, you may open the line for questions.

Q&A Session

Operator: Thank you. Your first question comes from Aaron Grey with Alliance Global Partners. Please go ahead.

Aaron Grey: Hi, good morning, and thank you for the questions. So first question for me I just want to go back into some commentary on the prepared remarks regarding Massachusetts. I believe you talked about some stabilization. I think you’re talking about the wholesale market there. So I just wanted to get some further color there, because we’re continuing to see pricing pressure at the retail level. So I want to know your thoughts on that, whether or not you think that’s sustainable, particularly with some of the neighboring states with Connecticut, in Rhode Island going to be starting adult use sales soon? And just in terms of that stabilization is that more dynamic of your own, strains in genetics because you think differentiate and it’s more commoditization with some of the other strains or if there’s something else going on with those dynamics? Thank you.

Tim Shaw: Thanks, Aaron. This is Tim. Great question. The stabilization, yes, we were really bullish and we’re a true brand company. Our Nature’s Heritage brand has continued to buck the trend. We stay at a premium above the rest and we’ve brought in-house to help keep our top brands at the premium level and in-house has really grown in our wholesale market to compete with all those trends of value needs and value adds.

Aaron Grey: Okay, great. Thank you very much for that color. And then just turning to Michigan where you guys recently launched some of their brands there, just what of your thoughts on that market? It’s another one we’ve seen a lot of pricing pressure, kind of also by some volume growth. So just what are your thoughts in terms of the timing and when you were looking into enter the Michigan market, given, a lot of the dynamics and that being one of the market, seeing more of the pricing pressure? Thanks.

Jon Levine: Yes, good morning, Aaron. Thank you very much for joining the call this morning. Yes, Michigan, we went in there with agreement to expand our brands into that state, which we’re very excited to bring our award-winning brands, Betty’s Eddies and in the future, our others. But we went into that market knowing that it’s a very big market with a lot of retail and flower distributors already. So we’re concentrating on an area that we feel we could target first to figure out what the market is like before we try to become vertical, if even €“ if we have the opportunity.

Aaron Grey: Okay, great. Thanks for the color. I’ll jump back into the queue.

Operator: Your next question comes from Andrew Semple with Echelon Capital Markets. Please go ahead.

Andrew Semple: Good morning. Thank you for taking my question. First off, just want to ask with value kind of tier products, making it more of the revenue mix, how do you €“ how do the gross margins on these products compare with the gross margins on your generally more premium product line, and how should we be thinking of that impacting maybe the margin profile in 2023?